drugset / Trial / NCT05520892

Summary

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

Timeline

Start
2022-10-06
Primary completion
2025-08-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.4 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 1 g/kg Intravenous